Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States.
The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease.
The company was incorporated in 2008 and is based in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 9, 21 | -5.34 Decreased by -67.92% | -1.82 Decreased by -193.41% |
| May 13, 21 | -45.60 Decreased by -1.42 K% | -0.92 Decreased by -4.86 K% |
| Mar 11, 21 | -2.64 Increased by +20.00% | -2.04 Decreased by -29.41% |
| Nov 12, 20 | -3.36 Increased by 0.00% | -3.06 Decreased by -9.80% |
| Aug 10, 20 | -3.18 Increased by +14.52% | -2.73 Decreased by -16.48% |
| May 12, 20 | -3.00 Increased by +19.35% | -2.46 Decreased by -21.95% |
| Mar 10, 20 | -3.30 Increased by +35.29% | -3.69 Increased by +10.57% |
| Nov 7, 19 | -3.36 Increased by +30.00% | -3.82 Increased by +12.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 21 | 0.00 Decreased by N/A% | -7.47 M Increased by +21.48% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 21 | 0.00 Decreased by N/A% | -170.08 M Decreased by -2.04 K% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 20 | 0.00 Decreased by N/A% | -8.98 M Decreased by -35.82% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 20 | 0.00 Decreased by N/A% | -10.86 M Decreased by -66.75% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 20 | 0.00 Decreased by N/A% | -9.51 M Decreased by -33.33% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 20 | 0.00 Decreased by N/A% | -7.95 M Decreased by -31.70% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 19 | 0.00 Decreased by N/A% | -6.61 M Decreased by -9.08% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 19 | 0.00 Decreased by N/A% | -6.51 M Decreased by -14.70% | Decreased by N/A% Decreased by N/A% |